Clinical trials: Vascular Endothelial Growth Factor
Age Related Macular Degeneration, Exudative Age-Related Macular Degeneration
Real-Life Clinical Outcomes of Aflibercept Biosimilar MY-1701P in the Treatment of Exudative Age-Related Macular Degeneration
In this study, patients receiving Eylea treatment will be treated with Yesafili, a biosimilar molecule, and routine examination results will be noted.
- Conditions
- Age Related Macular Degeneration, Exudative Age-Related Macular Degeneration, Anti Vascular Endothelial Growth Factor
- Trial name
- NCT07235527
- Testing
- Aflibercept biosimilar (MY-1701P)
- Where
- Turkey (Türkiye)
- Volunteers
- 54 people
- Sponsor
- Saglik Bilimleri Universitesi
Diabetic Macular Edema, Visual Impairment
Evaluation of Serum- and OCT Biomarkers in Patients With DME Treated With Anti-VEGF or Dexamethasone Implant
This study aims to investigate the association between serum biomarkers and clinical response to anti-VEGF or dexamethasone implant by assessing OCT-biomarkers in patients with diabetic macular edema, DME, and to compare these…
- Conditions
- Diabetic Macular Edema, Visual Impairment, Diabetes Mellitus, Hyperglycaemia (Diabetic)
- Trial name
- BiomarkerOCT (NCT06984822)
- Testing
- Anti-VEGF treatment, Dexamethasone implant, Treatment with intravitreal anti-VEGF OR Dexamethasone implant
- Where
- 2 sites in Sweden
- Volunteers
- 150 people
- Sponsor
- Vastra Gotaland Region
Age-related Macular Degeneration (ARMD), Choroidal Neovascularization
Long Term Efficacy of Faricimab Using a Treat and Extend Regimen for Type 3 Macular Neovascularization
Type 3 macular neovascularization (MNV) is a subtype of neovascular age-related macular degeneration accounting for 10-20% of cases, notable for high rates of bilateral involvement and risk of profound vision loss, particularly…
- Conditions
- Age-related Macular Degeneration (ARMD), Choroidal Neovascularization, Anti-vascular Endothelial Growth Factor
- Trial name
- NCT07187804
- Testing
- Intravitreal faricimab injection
- Where
- South Korea
- Volunteers
- 30 people
- Sponsor
- Kim's Eye Hospital
Glaucoma, Neovascular, Vascular Endothelial Growth Factor Overexpression
Intracameral Versus Intravitreal Bevacizumab Injection in NVG: RCT
To prospect studying the efficacy and safety of treating NVG with the intracameral versus the intravitreal injection of Bevacizumab.
- Trial name
- NCT03648814
- Testing
- Intracameral injection, Intravitreal injection
- Where
- Thailand
- Volunteers
- 40 people
- Sponsor
- Prince of Songkla University
Diabetic Retinopathy, Diabetic Macular Edema
Exploring the Interaction Between Metabolic Disorders and NLPR3 Inflammasome Activation in DR Inflammatory Damage
Diabetic retinopathy (DR) is one of the most serious microvascular complications of diabetes. Early diagnosis and treatment of diabetes is the key to prevent visual impairment in DR patients.
- Conditions
- Diabetic Retinopathy, Diabetic Macular Edema, Anti-vascular Endothelial Growth Factor
- Trial name
- DR (NCT06272565)
- Where
- China
- Volunteers
- 240 people
- Sponsor
- Zhongshan Ophthalmic Center, Sun Yat-sen University
Proliferative Diabetic Retinopathy, Vascular Endothelial Growth Factor Overexpression
Macular Perfusion Changes After Anti-VEGF Versus Targeted Retinal Photocoagulation in Proliferative Diabetic Retinopathy
Diabetic retinopathy (DR) is the most common microvascular complication of diabetes mellitus (DM), while proliferative diabetic retinopathy (PDR) is the principal cause of severe visual loss in patients with diabetes.
- Conditions
- Proliferative Diabetic Retinopathy, Vascular Endothelial Growth Factor Overexpression, Diabetic Retinopathy
- Trial name
- PROPER (NCT04674254)
- Testing
- Bevacizumab Injection, Targeted retinal photocoagulation, Standard pan-retinal photocoagulation
- Where
- Egypt
- Volunteers
- 43 people
- Sponsor
- Cairo University
Diabetic Macular Edema, Macular Ischemia
Effect of Ranibizumab Versus Bevacizumab on the Macular Perfusion in Diabetic Macular Edema
The Early Treatment Diabetic Retinopathy Study (ETDRS) group founded guidelines for treating patients with clinically significant diabetic macular edema (DME) with focal/grid macular laser photocoagulation.
- Conditions
- Diabetic Macular Edema, Macular Ischemia, Diabetic Retinopathy, Vascular Endothelial Growth Factor Overexpression
- Trial name
- REBEL (NCT04991350)
- Testing
- Intravitreal ranibizumab, Intravitreal bevacizumab
- Where
- Egypt
- Volunteers
- 5 people
- Sponsor
- Cairo University
Uveitis, Macular Edema
Effects of Conbercept in Refractory Uveitic Macular Edema and VEGF
As a primary exploratory study, this study aims to evaluate the short-term effectiveness of intravitreal Conbercept injection in UME, and to explore the correlation between inflammatory factors like VEGF and the responsiveness to…
- Conditions
- Uveitis, Macular Edema, Vascular Endothelial Growth Factor, Effect of Drugs
- Trial name
- NCT04296838
- Testing
- intravitreal injection of Conbercept
- Where
- China
- Volunteers
- 5 people
- Sponsor
- Peking Union Medical College Hospital
Vascular Endothelial Growth Factor Overexpression
Effect of Plasma Rich in Growth Factors on Semen Quality
The hypothesis is growing semen samples with plasma rich in growth factors (PRGF), because it could improve sperm motility in patients subsidiary TRA, ultimately improving pregnancy rates.
- Trial name
- NCT02708537
- Testing
- PRGF in candidates for sperm donors
- Where
- 3 sites in Spain
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- IVI Bilbao
Recurrent Cervical Carcinoma, Persistent Advanced Cervical Carcinoma
First-line Chemotherapy for Recurrent Cervical Cancer
The response rate of traditional first-line chemotherapy for recurrent or persistent advanced cervical cancer was low. This single arm, open, phase II trial would recruit 37 eligible patients.
- Conditions
- Recurrent Cervical Carcinoma, Persistent Advanced Cervical Carcinoma, Chemotherapy, Vascular Endothelial Growth Factor 2 Inhibitor
- Trial name
- NCT04188847
- Testing
- Chemotherapy plus apatinib
- Where
- China
- Volunteers
- 37 people
- Sponsor
- Lei Li
Intraocular Pressure, Neovascular Glaucoma
Aflibercept as Adjunctive Treatment for Filtration Surgery in Neovascular Glaucoma
Purpose: To investigate intravitreal aflibercept (IVA) injection as an adjunctive treatment to trabeculectomy with mitomycin C (TMC) and panretinal photocoagulation (PRP) for neovascular glaucoma (NVG).
- Conditions
- Intraocular Pressure, Neovascular Glaucoma, Vascular Endothelial Growth Factor Overexpression, Glaucoma Secondary to Eye Inflammation
- Trial name
- NCT04970251
- Testing
- Aflibercept Ophthalmic
- Where
- Thailand
- Volunteers
- 5 people
- Sponsor
- Siriraj Hospital
Macular Degeneration, Anti Vascular Endothelial Growth Factor
Effect Aflibercept on Ocular Perfusion
Age-related macular degeneration (AMD) is the leading cause of irreversible visual impairment in Western Countries. It is a well-established fact that vascular endothelial growth factor (VEGF) plays a key part in the development…
- Trial name
- NCT03804099
- Testing
- Aflibercept Injection [Eylea]
- Where
- Austria
- Volunteers
- 20 people
- Sponsor
- Augenabteilung Allgemeines Krankenhaus Linz
Vascular Endothelial Growth Factor Overexpression
Differential Regulation of VEGF, Cadherin, Angiopietin 2 by Trigger Oocyte Maturation With GnRHa vs hCG in Donors
Introduction OHSS still remains a complication of assisted reproduction treatments. hCG administration to trigger final oocyte maturation will release vascular mediators, being VEGF and other proteins such as VE-Cadherin or…
- Trial name
- NCT00848185
- Volunteers
- 96 people, healthy volunteers welcome
- Sponsor
- IVI Madrid
Ovarian Hyperstimulation Syndrome, GnRH Antagonist
Preventive Application of GnRH Antagonist on Early OHSS
Ovarian hyperstimulation syndrome is an iatrogenic complication of controlled ovarian stimulation. Ovarian hyperstimulation syndrome prevention is a multistage process and more important than treatment.Preventive administration…
- Conditions
- Ovarian Hyperstimulation Syndrome, GnRH Antagonist, Aspirin, Vascular Endothelial Growth Factor
- Trial name
- NCT03188471
- Testing
- GnRH antagonist, aspirin
- Where
- China
- Volunteers
- 175 people
- Sponsor
- First Affiliated Hospital, Sun Yat-Sen University
Adult Hepatocellular Carcinoma, Recurrent Hepatocellular Carcinoma
Oral Thalidomide and Tegafur-uracil to Decrease Hepatocellular Carcinoma Recurrence
This single-centered phase II clinical study is to obtain preliminary information on 1-year recurrence-free survival rate, recurrence-free survival and safety profile of thalidomide in combination with tegafur-uracil in…
- Conditions
- Adult Hepatocellular Carcinoma, Recurrent Hepatocellular Carcinoma, Adverse Reaction to Drug, Vascular Endothelial Growth Factor Overexpression
- Trial name
- NCT02447679
- Testing
- thalidomine, tegafur-uracil
- Where
- Taiwan
- Volunteers
- 40 people
- Sponsor
- Chang Gung Memorial Hospital
Vascular Endothelial Growth Factor Overexpression, Membrane Alteration
Perforated Barrier Membranes Maintain Physiologic Gingival Crevicular Fluid Growth Factor Levels
Membrane modifecation: Guided tissue membrane perforations may serve as a more biologic scaffold that could allow for the free passage of biologic mediators from the periosteum and overlying gingival connective tissue into the…
- Trial name
- NCT02168322
- Testing
- collagen membrane
- Where
- Egypt
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Al-Azhar University
Macular Degeneration, Regional Blood Flow
The Effect of a Single Intravitreal Anti-VEGF Therapy on Optic Nerve Head Perfusion
Age related macula degeneration is one of the most common sight threatening diseases of the elderly. The so called wet form of AMD is caused by choroidal neovascularisation (CNV) of pathological vessels, which lead to leakage…
- Conditions
- Macular Degeneration, Regional Blood Flow, Vascular Endothelial Growth Factor
- Trial name
- NCT00709657
- Testing
- ranibizumab, bevacizumab or pegaptanib
- Where
- Austria
- Volunteers
- 8 people
- Sponsor
- Medical University of Vienna
Vascular Endothelial Growth Factor, Macular Degeneration
Macugen Observational Study
The objective of this observational study is to evaluate the effectiveness and safety of Macugen for treatment of wet age-related macular degeneration (AMD) in Indian patients.Prospective, Observational, Non-interventional Study.
- Trial name
- NCT00735943
- Testing
- No intervention
- Where
- 5 sites in India
- Volunteers
- 22 people
- Sponsor
- Pfizer